This is a preview of subscription content, log in via an institution to check access.
References
Ligand Pharmaceuticals, Royalty Pharma. Ligand, Royalty Pharma Amend SERM Royalty Agreement; Royalty Pharma Accelerates and Increases Royalty Purchase to $32.5 Million as Substitute for Final Two Options. Media Release: 9 Nov 2004. Available from URL: http://www.ligand.com
Wyeth. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year. Media Release: 31 Jan 2008. Available from URL: http://www.wyeth.com
Wyeth. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene). Media Release: 14 Dec 2007. Available from: URL: http://www.wyeth.com
Wyeth Pharmaceuticals. Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis. Media Release: 24 Apr 2007. Available from URL: http://www.wyeth.com
Ligand Pharmaceuticals Incorporated. Ligand Earns Milestone metaas Wyeth Submits NDA for Bazedoxifene for Osteoporosis; One of Three Phase III SERM Products Advancing Prospects of Future Royalties. Media Release: 26 Jun 2006. Available from URL: http://www.ligand.com
Miller PD, Christiensen C, Hoeck HC, et al. Efficacy of bazedoxifene for prevention of postmenopausal osteoporosis: results of a 2-year, phase III, placebo- and active-controlled study. Journal of Bone and Mineral Research 22 (Suppl. 1): 59, 1 Sep 2007
Wyeth Pharmaceuticals. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis. Media Release: 19 Sep 2007. Available from URL: http://www.wyeth.com
Ermer JC, Kotake A, McKeand WE, et al. Clinical pharmacology of a novel tissue selective estrogen (WAY-140424) in postmenopausal women following administration for 30 days. Journal of Bone and Mineral Research 15 (Suppl. 1): 436 (plus poster), Sep 2000
Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, menopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. Journal of Bone and Mineral Research 22 (Suppl. 1): 58, 1 Sep 2007
Ronkin S, Maru B, Baracat E, et al. TSE-424, a novel tissue selective estrogen, demonstrates dose-dependent estrogen antagonist effect on endometirum. 12th Annual Meeting of the North American Menopause Society: 62 (plus oral presentation), 4 Oct 2001
Ronkin S, Baracat E, Roma L, et al. TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion. 83rd Annual Meeting of the Endocrine Society: abstr. P3–145, 20 Jun 2001
Komm BS, PVN, Minck DR. Effects of bazedoxifene acetate on bone loss: a 12-month study in ovariectomised rats. Journal of Bone and Mineral Research 22 (Suppl. 1): 206, 1 Sep 2007
Komm BS, Miller CP, Lyttle CR. WAY-140424, a third generation tissue selective estrogen with a potentially improved therapeutic profile. Journal of Bone and Mineral Research 15 (Suppl. 1): 161 (plus oral presentation), Sep 2000
Collini MD, Tran BD, Komm BS, et al. Discovery and preclinical pharmacology of TSE-424, a novel tissue selective estrogen. 219th American Chemical Society National Meeting: abstr. MEDI 329, 26 Mar 2000
Rights and permissions
About this article
Cite this article
Bazedoxifene. Drugs R D 9, 191–196 (2008). https://doi.org/10.2165/00126839-200809030-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200809030-00007